Brief: Lantern Pharma & Starlight Therapeutics Present LP-184
26/11/2024 13:46
Nov 26 (Reuters) - Lantern Pharma Inc LTRN.O :
* LANTERN PHARMA & STARLIGHT THERAPEUTICS PRESENT LP-184
(STAR-001) PHASE 1B TRIAL DESIGN AND PRECLINICAL DATA IN
GLIOBLASTOMA AT SOCIETY FOR NEURO-ONCOLOGY (SNO) 2024
HIGHLIGHTING NOVEL SYNTHETIC LETHALITY
Source text: ID:nBw352z2ma
Further company coverage: LTRN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Reports HARMONIC Data Showing LP-300 Progression-Free Survival Benefit Deepens With Treatment Duration In EGFR Exon 21 L858R Lung Cancer
Brief: Lantern Pharma Announces Successful Outcome Of FDA Type C Meeting Request For Harmonic Phase 2 Trial of LP-300 In Never-Smokers With NSCLC
Lantern Pharma Q1 net loss narrows on R&D cost cuts
Brief: Lantern Pharma Inc. Announces Up To $9.25 Million Registered Direct Offering With Existing Holders And A Single Institutional Investor
Brief: Lantern Pharma Inc - Schedules Type C FDA Meeting For Harmonic Protocol Amendments